The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable

About this episode

Darshan Kulkarni discusses the challenges and risks associated with AI in drug discovery and its implications for patentability.

Send us Fan Mail "The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments. We dive deep into the three pillars of risk that can sink a biotech firm: Data Integrity: Why AI scales bad data faster than you can fix it.The Ownership Crisis: Wh...

People in this episode

Host: Darshan Kulkarni

Topics covered

• AI in drug discovery
• biotech risks
• data integrity
• patentability
• life sciences
• regulatory compliance

Keywords

• AI-generated drugs
• patentable
• data integrity
• biotech
• regulatory compliance
• life sciences
• ownership crisis

More episodes of DarshanTalks Podcast

• Unlicensed Medical Advice & The Legal Battle Over Character.AI · May 18, 2026 · 15 min
• Sponsoring Cannabis Research · May 6, 2026 · 5 min
• The New Era of Personal Consent Decrees · April 30, 2026 · 8 min
• Why Private Membership Associations Fail FDA Scrutiny · April 16, 2026 · 7 min
• The Hidden Reason Sites are Firing Recruiters · April 11, 2026 · 8 min
• Don’t Let Your PI Walk Away With Your Study · April 10, 2026 · 1 min